Navigation Links
De nouvelles données mettent en évidence le fardeau considérable que représente la nycturie
Date:3/17/2013

>Une baisse de 24 % de la productivité au travail a été observée chez les patients nycturiques.  Il s'agit d'un chiffre plus élevé que celui rapporté pour l'hyperactivité vésicale (10-12 %)[4] et comparable à ceux d'autres maladies chroniques non urologiques telles que le RGO (25 %),[5] l'asthme sévère (21 %),[6] la BPCO (19 %)[7] et la constipation (34 %)[8]. De plus, la capacité des patients à exercer des activités dans la journée a été réduite de 34 %.[1]

Philip Van Kerrebroeck , MD, PhD, université de Maastricht a commenté les résultats de cette étude en déclarant : « La nycturie est un problème commun qui affecte environ un tiers des adultes, mais son fardeau est sous-estimé et souvent considéré comme étant moins grave que d'autres maladies chroniques en termes de qualité de vie et de coût pour la société.  Ces données montrent que tout comme d'autres maladies, la nycturie a un impact négatif sur  le sommeil, les performances dans la journée et la productivité au travail. Les patients qui en souffrent doivent consulter pour traiter spécifiquement cette maladie invalidante. »

La deuxième série de données présentées à l'EAU consistait en une analyse de données subjectives, rapportées par des patients, sur les symptômes qu'ils considèrent comme étant les plus gênants.  Les nombreux effets négatifs sur la qualité de vie associés à la nycturie avaient déjà été documentés, mais aucune étude jusque-là n'avait demandé aux patients d'expliquer pourquoi cette affe
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Elsevier Launches Evidence-Based, Collaborative Order Sets Solution
2. More evidence needed for scale up of mobile device technology in health
3. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
4. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
5. endpoint Adopts New Technology To Boast Most Robust IVR Validation Objective Evidence and Decrease IVR Build Timelines
6. New Epidemiological Data Provide Additional Safety Evidence for Lantus®
7. More evidence for longevity pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  US-Australian drug discovery company, Novogen ... confirmed its comprehensive scientific review has identified high ... areas of unmet patient need. Novogen is moving ... projects prior to entering into Phase 1 clinical ... Acting Chief Executive Officer, Iain Ross , ...
(Date:8/31/2015)... 2015 FLX Bio, Inc., a biopharmaceutical company ... immunotherapies, announced today that it has appointed Brian ... William Ho , M.D., Ph.D., as Chief Medical ... team led by veterans of Flexus Biosciences, Inc., FLX,s ... Officer; Jay Powers , Ph.D., Vice President, Drug ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Food Processing Suppliers Association's ... processors, equipment manufacturers and leaders in the field of academia. , METTLER ... for manufacturers of bakery and snacks; beverages; dairy; meat, poultry and seafood; and ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2
... ... new partner and sponsor in Life Line Screening. The two companies aim to ... abdominal aortic aneurysm and , peripheral arterial disease screening . Life Line ... its customers can easily donate money to the foundation. , ...
... , SAN DIEGO, Dec. 9 ... top-line efficacy and safety results from the Tulip PETAL Study ... proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in ... data from the Tulip PETAL Study are consistent with what ...
... , Nashville, Tenn., Dec. 9 Cumberland Pharmaceuticals ... entered into an exclusive agreement with DB Pharm Korea Co. ... ( ibuprofen ) Injection in South Korea. Designed to treat pain ... U.S. Food and Drug Administration and launched by Cumberland in the ...
Cached Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... Studies show the incidence of diabetes in dogs has increased ... Missouri veterinarians have changed the way veterinarians treat diabetes in ... humans. Dogs are susceptible to type 1, insulin-dependent diabetes. ... because their bodies do not produce enough insulin, a hormone ...
... around the world have forced many species to the brink ... multiple causes that are still not fully understood, researchers conclude ... causative factor is often missing the larger picture, they said, ... don,t consider the totality of causes or could even ...
... April 25, 2011 - Call them the Jason Bournes of ... secret agents, some bacteria avoid antibiotic treatments by essentially shutting ... says Thomas Wood, professor in the Artie McFerrin Department of ... elaborate survival mechanism is explained in the online April edition ...
Cached Biology News:MU researchers pioneer animal diabetes treatment 2Catastrophic amphibian declines have multiple causes, no simple solution 2Catastrophic amphibian declines have multiple causes, no simple solution 3'Going off the grid' helps some bacteria hide from antibiotics 2'Going off the grid' helps some bacteria hide from antibiotics 3